Differential Role of Smad2 and Smad3 in the Acquisition of an Endovascular Trophoblast-Like Phenotype and Preeclampsia.


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2020
Historique:
received: 02 04 2020
accepted: 02 06 2020
entrez: 1 8 2020
pubmed: 1 8 2020
medline: 29 5 2021
Statut: epublish

Résumé

During placental development, cytotrophoblast progenitor cells differentiate into the syncytiotrophoblast and invasive extravillous trophoblasts (EVTs). Some EVTs further differentiate into endovascular trophoblasts (enEVTs) which exhibit endothelial-like properties. Abnormal placental development, including insufficient enEVT-mediated remodeling of the uterine spiral arteries, is thought to be a precipitating factor in the onset of preeclampsia (PE), a pregnancy-related hypertensive disorder. Several members of the transforming growth factor-β (TGF-β) superfamily, such as TGF-βs, Nodal, and Activin have been reported to either promote or inhibit the invasive EVT pathway. These ligands signal through serine/threonine receptor complexes to activate downstream signaling mediators, Smad2 and Smad3. In this study, we determined Smad2 and Smad3 expression pattern in placenta and their effects on trophoblast invasion and differentiation. Total Smad2/3 levels were relatively constant across gestation while the ratio of active phosphorylated forms to their total levels varied with gestational stages, with a higher pSmad2/total Smad2 in later gestation and a higher pSmad3/total Smad3 in early gestation. Immunofluorescent staining revealed that pSmad3 was localized in nuclei of EVTs in anchoring villi. On the other hand, pSmad2 was mostly absent in this invasive EVT population. In addition, pSmad3/total Smad3, but not pSmad2/total Smad2, was significantly lower in both early onset and late onset PE cases, as compared to gestational age-matched controls. Functional studies carried out using a first trimester trophoblast cell line, HTR-8/SVneo, and first trimester human placental explants showed that Smad2 and Smad3 had differential roles in the invasive pathway. Specifically, siRNA-mediated knockdown of Smad2 resulted in an increase in trophoblast invasion and an upregulation of mRNA levels of enEVT markers while the opposite was observed with Smad3 knockdown. In addition, Smad2 siRNA accelerated the EVT outgrowth in first trimester placental explants while the Smad3 siRNA reduced the outgrowth of EVTs when compared to the control. Furthermore, knockdown of Smad2 enhanced, whereas overexpression of Smad2 suppressed, the ability of trophoblasts to form endothelial-like networks. Conversely, Smad3 had opposite effects as Smad2 on network formation. These findings suggest that Smad2 and Smad3 have opposite functions in the acquisition of an enEVT-like phenotype and defects in Smad3 activation are associated with PE.

Identifiants

pubmed: 32733385
doi: 10.3389/fendo.2020.00436
pmc: PMC7362585
doi:

Substances chimiques

SMAD2 protein, human 0
SMAD3 protein, human 0
Smad2 Protein 0
Smad3 Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

436

Subventions

Organisme : CIHR
ID : PJT-153146
Pays : Canada
Organisme : CIHR
ID : CCI-132565
Pays : Canada
Organisme : CIHR
ID : FDN-143262
Pays : Canada
Organisme : CIHR
ID : FDN-148368
Pays : Canada
Organisme : CIHR
ID : MGC-13299
Pays : Canada

Informations de copyright

Copyright © 2020 Brkić, Dunk, Shan, O'Brien, Lye, Qayyum, Yang, Matthews, Lye and Peng.

Références

Reproduction. 2018 Jun;155(6):R259-R271
pubmed: 29615475
Sci Rep. 2018 Jun 12;8(1):8977
pubmed: 29895842
Front Biosci. 2003 Sep 01;8:s1280-303
pubmed: 12957874
Cell Death Differ. 2017 Oct;24(10):1772-1783
pubmed: 28731464
Front Immunol. 2018 Aug 08;9:1661
pubmed: 30135684
Cell. 1998 Mar 20;92(6):797-808
pubmed: 9529255
Curr Pharm Biotechnol. 2018;19(10):771-780
pubmed: 29701150
Histol Histopathol. 2007 Mar;22(3):227-34
pubmed: 17163397
J Cell Mol Med. 2018 Nov;22(11):5378-5393
pubmed: 30256530
J Clin Invest. 1999 Jun;103(12):1641-50
pubmed: 10377170
PLoS One. 2011;6(7):e21990
pubmed: 21760941
Genes Dev. 1999 Apr 1;13(7):804-16
pubmed: 10197981
Science. 2002 May 31;296(5573):1646-7
pubmed: 12040180
Hypertension. 2013 Apr;61(4):864-72
pubmed: 23424236
Int J Mol Sci. 2019 Dec 31;21(1):
pubmed: 31906245
Cell Signal. 2014 Sep;26(9):1935-42
pubmed: 24863882
Mol Cell Endocrinol. 2001 Apr 25;175(1-2):111-21
pubmed: 11325521
Placenta. 2005 Apr;26 Suppl A:S21-30
pubmed: 15837062
J Biol Chem. 2003 Mar 28;278(13):11721-8
pubmed: 12547835
Placenta. 2018 Aug;68:44-51
pubmed: 30055669
J Biol Chem. 2013 Nov 15;288(46):33181-92
pubmed: 24106276
Nat Cell Biol. 2004 Apr;6(4):366-72
pubmed: 15104092
Histochem Cell Biol. 2018 Oct;150(4):361-370
pubmed: 30046889
Cell Biol Int. 2018 Sep;42(9):1259-1264
pubmed: 29663570
J Biol Chem. 2013 Apr 12;288(15):10265-74
pubmed: 23393131
FASEB J. 2019 May;33(5):6281-6295
pubmed: 30789794
J Clin Endocrinol Metab. 2012 Aug;97(8):E1370-9
pubmed: 22685232
J Am Soc Nephrol. 2002 Nov;13(11):2657-66
pubmed: 12397035
Cell. 1998 Sep 18;94(6):703-14
pubmed: 9753318
Sci Signal. 2019 Feb 26;12(570):
pubmed: 30808818
Biol Reprod. 2003 Jul;69(1):1-7
pubmed: 12620937
Biol Reprod. 2000 Mar;62(3):739-47
pubmed: 10684818
Placenta. 2012 Sep;33(9):696-703
pubmed: 22710193
Mol Ther. 2018 Sep 5;26(9):2189-2205
pubmed: 30061037
Mol Aspects Med. 2013 Oct;34(5):981-1023
pubmed: 23276825
Biol Reprod. 2003 May;68(5):1719-26
pubmed: 12606401
PLoS One. 2016 May 24;11(5):e0156038
pubmed: 27218821
Oncogene. 1999 Feb 25;18(8):1643-8
pubmed: 10102636
Oncotarget. 2017 May 16;8(20):33560-33570
pubmed: 28432277
Wiley Interdiscip Rev Dev Biol. 2013 Jan-Feb;2(1):47-63
pubmed: 23799630
Biol Reprod. 2020 Feb 12;102(1):18-26
pubmed: 31566220
Am J Pathol. 2011 Mar;178(3):1177-89
pubmed: 21356369
Cell. 1998 Sep 4;94(5):585-94
pubmed: 9741623
Mol Endocrinol. 2007 Oct;21(10):2472-86
pubmed: 17595316
Reproduction. 2010 Apr;139(4):789-98
pubmed: 20133364
Biochem Biophys Res Commun. 2013 Mar 1;432(1):116-22
pubmed: 23376068
EXCLI J. 2019 Oct 31;18:Doc1007
pubmed: 31762725
Biomed Res Int. 2013;2013:243649
pubmed: 23586024
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12595-600
pubmed: 10535967
Endocrinology. 2017 Oct 1;158(10):3620-3628
pubmed: 28977597
Endocr Pathol. 2006 Spring;17(1):19-33
pubmed: 16760577
J Cell Sci. 2013 Jan 15;126(Pt 2):445-53
pubmed: 23230143
Sci Rep. 2016 Feb 24;6:21602
pubmed: 26905010
Biol Reprod. 2012 Aug 30;87(2):47
pubmed: 22674391
Hypertension. 2013 Dec;62(6):1046-54
pubmed: 24060885
Cytometry A. 2004 Apr;58(2):167-76
pubmed: 15057970
J Clin Endocrinol Metab. 2015 Nov;100(11):E1415-27
pubmed: 26305619
J Vis Exp. 2016 Nov 17;(117):
pubmed: 27911396
Am J Obstet Gynecol. 2011 Mar;204(3):193-201
pubmed: 21094932
Placenta. 2009 Nov;30(11):939-48
pubmed: 19766308
Exp Cell Res. 1993 Jun;206(2):204-11
pubmed: 7684692
Development. 2019 Nov 27;146(22):
pubmed: 31776138
Development. 2007 Jan;134(1):65-75
pubmed: 17138664
Nat Rev Nephrol. 2014 Aug;10(8):466-80
pubmed: 25003615
Exp Cell Res. 2005 Feb 1;303(1):101-13
pubmed: 15572031
Nat Rev Nephrol. 2019 May;15(5):275-289
pubmed: 30792480
J Cell Sci. 2012 Jul 1;125(Pt 13):3124-32
pubmed: 22454525
Hypertension. 2014 Jun;63(6):1276-84
pubmed: 24664294
Endocrinology. 1997 Sep;138(9):3976-86
pubmed: 9275089
Placenta. 2017 Sep;57:17-25
pubmed: 28864007
Placenta. 2017 Feb;50:1-7
pubmed: 28161053
Endocrinology. 2016 Feb;157(2):883-99
pubmed: 26653761
Biol Reprod. 2005 Aug;73(2):374-81
pubmed: 15858216
J Obstet Gynaecol Can. 2003 Oct;25(10):834-44
pubmed: 14532952
J Biol Chem. 2002 Nov 1;277(44):41361-8
pubmed: 12193595

Auteurs

Jelena Brkić (J)

Department of Biology, York University, Toronto, ON, Canada.

Caroline Dunk (C)

Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.

Yanan Shan (Y)

Department of Biology, York University, Toronto, ON, Canada.

Jacob Anderson O'Brien (JA)

Department of Biology, York University, Toronto, ON, Canada.

Phetcharawan Lye (P)

Department of Physiology, University of Toronto, Toronto, ON, Canada.

Sheza Qayyum (S)

Department of Biology, York University, Toronto, ON, Canada.

Peifeng Yang (P)

Department of Biology, York University, Toronto, ON, Canada.

Stephen G Matthews (SG)

Department of Physiology, University of Toronto, Toronto, ON, Canada.

Stephen J Lye (SJ)

Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Department of Physiology, University of Toronto, Toronto, ON, Canada.

Chun Peng (C)

Department of Biology, York University, Toronto, ON, Canada.
Centre for Research in Biomolecular Interactions, York University, Toronto, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH